

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 June 2009 (25.06.2009)

PCT

(10) International Publication Number
WO 2009/077736 A4

(51) International Patent Classification:

A61K 31/138 (2006.01) A61K 31/385 (2006.01)
A61K 31/4178 (2006.01) A61K 31/4168 (2006.01)
A61K 31/496 (2006.01) A61P 27/02 (2006.01)
A61K 31/498 (2006.01)

(21) International Application Number:

PCT/GB2008/004129

(22) International Filing Date:

15 December 2008 (15.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0724558.2 15 December 2007 (15.12.2007) GB

(71) Applicant and

(72) Inventor: SHARMA, Anant [GB/GB]; 37 Pemberley Avenue, Bedford MK40 2LE (GB).

(74) Agent: BANFORD, Jonathan; Franks & Co (South) Limited, Carlton House, 26 Billing Road, Northampton NN1 5AT (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,

EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with amended claims (Art. 19(1))

(88) Date of publication of the international search report:

30 December 2009

Date of publication of the amended claims: 25 February 2010

(54) Title: A MEDICAMENT COMPRISING A PARASYMPATHETIC AGONIST AND A SYMPATHETIC ANTAGONIST OR A SYMPATHETIC AGONIST

(57) Abstract: A medicament for topical administration to a human or animal eye comprises at least two pharmacologically active agents. One of the active agents is a parasympathetic agonist, such as pilocarpine, and the other active agent is either a sympathetic antagonist such as dapiprazole or thymoxamine, or a sympathetic agonist such as brimonidine or iopidine. The medicament is preferably in the form of a liquid composition, such as eye drops, or a gel or ointment and may comprise a slow-release composition. The medicament acts to improve visual acuity for a period of several hours, and may be beneficial in cases of presbyopia, myopia, hypermetropia, astigmatism and/or impaired night vision.



WO 2009/077736 A4

AMENDED CLAIMS
received by the International Bureau on 18th December 2009 (18.12.09)

1. A use of a combination of a first pharmacologically active agent comprising a parasympathetic agonist and a second pharmacologically active agent comprising a sympathetic antagonist or a sympathetic agonist in the manufacture of a medicament adapted for topical application to a human or animal eye in order to improve visual acuity.
2. A use of a combination of pharmacologically active agents as claimed in claim 1, wherein the medicament is adapted for topical application to treat defects of visual acuity.
3. A use of a combination of pharmacologically active agents as claimed in either claim 1 or claim 2, wherein the medicament is adapted for topical application to correct defects of visual acuity.
4. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein the medicament is adapted for topical application to treat symptomatically conditions comprising defects of visual acuity.
5. A use of combination of pharmacologically active agents as claimed in any of the preceding claims, wherein the medicament comprises a liquid composition, gel or ointment.

6. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein the medicament comprises a slow release composition, optionally comprising slow release insert means.
7. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said parasympathetic agonist comprises pilocarpine.
8. A use of a combination of pharmacologically active agents as claimed in claim 7, wherein the medicament comprises between 0.05% and 4% pilocarpine, optionally at least 0.25% and optionally no more than approximately 0.5% pilocarpine.
9. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein the second active agent comprises a sympathetic antagonist adapted to act as an α -receptor blocker.
10. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said sympathetic antagonist comprises dapiprazole.
11. A use of a combination of pharmacologically active agents as claimed in claim 10, wherein the medicament comprises between 0.05% and 4% dapiprazole, optionally at least 0.25% and optionally no more than approximately 0.5% dapiprazole.
12. A use of a combination of pharmacologically active agents as claimed in any one of claims 1 to 9, wherein said sympathetic antagonist comprises thymoxamine.

13. A use of a combination of pharmacologically active agents as claimed in claim 12, wherein the medicament comprises between 0.05% and 4% thymoxamine, optionally at least 0.25% and optionally no more than approximately 0.5% thymoxamine.
14. A use of a combination of pharmacologically active agents as claimed in any one of claims 1 to 8, wherein the sympathetic antagonist comprises a β -blocker.
15. A use of a combination of pharmacologically active agents as claimed in any one of claims 1 to 8, wherein the second active agent comprises a sympathetic agonist.
16. A use of a combination of pharmacologically active agents as claimed in claim 15, wherein said sympathetic agonist comprises brimonidine.
17. A use of a combination of pharmacologically active agents as claimed in claim 16, wherein the medicament comprises between 0.01% and 4% brimonidine, and optionally at least about 0.1% brimonidine.
18. A use of a combination of pharmacologically active agents as claimed in claim 17, wherein said sympathetic agonist comprises iopidine.
19. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said medicament is adapted to treat presbyopia.

20. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said medicament is adapted to treat myopia.
21. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said medicament is adapted to treat hypermetropia.
22. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said medicament is adapted to improve night or low-light vision.
23. A use of a combination of pharmacologically active agents as claimed in any one of the preceding claims, wherein said medicament is adapted to treat astigmatism.
24. A method for improving visual acuity comprising the step of administering to an eye a combination of a first pharmacologically active agent comprising a parasympathetic agonist and a second pharmacologically active agent comprising a sympathetic antagonist or a sympathetic agonist.